| abstract |
1. The use of the peptide Ac-His-Trp-Ala-Val-Gly-His-Leu-NH2 or its deacetylated form for the preparation of a pharmaceutical composition for the treatment and / or prevention of a malignant tumor, autoimmune diseases, fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, diseases of the heart and blood vessels, and metabolic diseases. ! 2. The use of the peptide according to claim 1, where the malignant tumor, autoimmune disease, fibrosis, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and blood vessel disease or metabolic disease selected from HBV infection. ! 3. The use of the peptide according to claim 1 or 2 to obtain a composition for oral administration to newborns, toddlers and / or preschool children. !four. The use of the peptide according to claim 1 or 2 to obtain a lyophilized composition or a buffer liquid composition. ! 5. A pharmaceutical composition comprising the Ac-His-Trp-Ala-Val-Gly-His-Leu-NH2 peptide or its deacetylated form together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotector, excipient and / or diluent. ! 6. The pharmaceutical composition according to claim 5 in the form of a lyophilisate or a liquid buffer solution. ! 7. The pharmaceutical composition according to claim 5 or 6, suitable for intravenous administration, oral administration or for administration by inhalation. ! 8. The pharmaceutical composition according to claim 5 or 6 in the form of a composition of artificial breast milk or a substitute for breast milk, suitable for oral delivery to newborns, toddlers and / or preschool children |